Value
8.2/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 8.7 |
| P/S | 10.0 |
| EV/EBITDA | 7.5 |
| Fwd P/E | 9.5 |
| PEG | 10.0 |
| Analyst target | 4.0 |
- ▸Forward P/E: 8.2x
- ▸PEG: 0.21
- ▸Attractively valued
ARDT · Why this verdict
Why Ardent Health (ARDT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score6.0/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company has beaten consensus earnings estimates in all four of the most recent quarters, with an average positive surprise of approximately 59% — a track record of consistent and substantial outperformance that suggests the business is either under-promising systematically or growing faster than analysts are modeling. Catalyst breakdown | The beat streak should extend for at least 2 more consecutive quarters with positive surprises exceeding 10%, confirming that the outperformance is structural rather than driven by estimate resets or one-time items. | →Stable |
| CounterA very high average surprise percentage can reflect analyst estimates that were reset too low following a period of uncertainty; if coverage initiates or expands at higher estimates, the streak could break simply because the bar is now set appropriately. | ||
Trading at a forward multiple of 7.2x with a PEG ratio of 0.18 and screening attractively valued against peers on price-to-earnings metrics, the stock offers a meaningful discount to the sector — and analyst consensus implies approximately 31% upside to their price target, suggesting institutional expectations are well above current levels. Valuation breakdown | The forward multiple should re-rate toward 10-12x over 12 months as earnings delivery continues; analyst price target convergence above $12 would confirm that the discount is being recognized by the market. | →Stable |
| CounterSmall-capitalization healthcare facilities companies can trade at persistent discounts due to regulatory, reimbursement, and operational risks that larger peers avoid; the cheap multiple may reflect a structural risk premium rather than a temporary mispricing. | ||
The 200-day moving average is declining at roughly 3% per month and the stock is trading below it — a confirmed downtrend — though the MACD indicator is improving and the RSI at 52 leaves room for recovery, indicating the stock may be attempting a turn rather than accelerating lower. Momentum breakdown | The 200-day moving average should flatten and then begin rising, with the stock reclaiming it, within the next 12 months for the technical backdrop to stop weighing on the fundamental thesis. | →Stable |
| CounterRising on-balance volume alongside a declining price and improving MACD is a classic divergence pattern that can precede a trend reversal; buyers accumulating on weakness could be the early signal of a recovery before the moving average turns. | ||
The put/call ratio is 11.00 — significantly elevated above normal levels — indicating that options market participants are paying heavily to hedge downside risk, which reflects institutional concern about near-term tail risk that is not yet visible in the fundamental data. Risk breakdown | The put/call ratio should decline below 3.0 over the next 12 months as the technical downtrend resolves and earnings delivery continues, signaling that the hedging pressure has normalized. | →Stable |
| CounterAn elevated put/call ratio can also reflect income-generating strategies (covered put writing) rather than pure bearish hedging; if option volumes are low in absolute terms, the ratio may overstate the degree of institutional concern. | ||
The company has beaten consensus earnings estimates in all four of the most recent quarters, with an average positive surprise of approximately 59% — a track record of consistent and substantial outperformance that suggests the business is either under-promising systematically or growing faster than analysts are modeling.
→StableCatalyst breakdown
- Expectation
- The beat streak should extend for at least 2 more consecutive quarters with positive surprises exceeding 10%, confirming that the outperformance is structural rather than driven by estimate resets or one-time items.
CounterA very high average surprise percentage can reflect analyst estimates that were reset too low following a period of uncertainty; if coverage initiates or expands at higher estimates, the streak could break simply because the bar is now set appropriately.
Trading at a forward multiple of 7.2x with a PEG ratio of 0.18 and screening attractively valued against peers on price-to-earnings metrics, the stock offers a meaningful discount to the sector — and analyst consensus implies approximately 31% upside to their price target, suggesting institutional expectations are well above current levels.
→StableValuation breakdown
- Expectation
- The forward multiple should re-rate toward 10-12x over 12 months as earnings delivery continues; analyst price target convergence above $12 would confirm that the discount is being recognized by the market.
CounterSmall-capitalization healthcare facilities companies can trade at persistent discounts due to regulatory, reimbursement, and operational risks that larger peers avoid; the cheap multiple may reflect a structural risk premium rather than a temporary mispricing.
The 200-day moving average is declining at roughly 3% per month and the stock is trading below it — a confirmed downtrend — though the MACD indicator is improving and the RSI at 52 leaves room for recovery, indicating the stock may be attempting a turn rather than accelerating lower.
→StableMomentum breakdown
- Expectation
- The 200-day moving average should flatten and then begin rising, with the stock reclaiming it, within the next 12 months for the technical backdrop to stop weighing on the fundamental thesis.
CounterRising on-balance volume alongside a declining price and improving MACD is a classic divergence pattern that can precede a trend reversal; buyers accumulating on weakness could be the early signal of a recovery before the moving average turns.
The put/call ratio is 11.00 — significantly elevated above normal levels — indicating that options market participants are paying heavily to hedge downside risk, which reflects institutional concern about near-term tail risk that is not yet visible in the fundamental data.
→StableRisk breakdown
- Expectation
- The put/call ratio should decline below 3.0 over the next 12 months as the technical downtrend resolves and earnings delivery continues, signaling that the hedging pressure has normalized.
CounterAn elevated put/call ratio can also reflect income-generating strategies (covered put writing) rather than pure bearish hedging; if option volumes are low in absolute terms, the ratio may overstate the degree of institutional concern.
TrendMatrix Research · core thesis
Engine thesis — one sentence
A perfect four-quarter earnings beat streak averaging nearly 60% above estimates, a forward multiple of 7.2x with a PEG of 0.18, and analyst consensus implying 31% upside build a compelling fundamental case — tempered by a confirmed price downtrend, an unusually elevated put/call ratio, and a spot reward-to-risk ratio that narrowly misses the entry threshold.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 4.6 |
| ROA | 2.8 |
| Gross margin | 7.7 |
| Op margin | 2.0 |
| Net margin | 1.0 |
| Current ratio | 7.4 |
| FCF quality | 6.3 |
| Moat | 6.2 |
| Piotroski F | 8.9 |
- ▸Strong Piotroski F-Score: 8/9
Growth
7.1/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 4.2 |
| EPS growth | 9.9 |
Momentum
7.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 9.8 |
| OBV | 10.0 |
| MA position | 8.0 |
| Volume | 3.5 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat
Sentiment
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.0 |
| Price target | 7.0 |
| erm sentiment | 5.0 |
Insider
5.3/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.5 |
| holder change | 5.1 |
- ▸Insider buying (low materiality) — $186,400 (0.012% of mkt cap)
Peer rank
4.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 8.4 |
| quality rank | 4.3 |
| growth rank | 4.9 |
Technical
2.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.1 |
| 52w position | 3.9 |
| gap | 5.0 |
Risk (lower is worse)
2.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.5 |
| days to cover | 4.4 |
| volatility | 2.4 |
| put call | 0.0 |
| implied vol | 0.0 |
| debt equity | 4.4 |
- ▸Elevated put/call: 4.00
- ▸High IV: 115%
- ▸Concentration risks: 2 MED (10-K Item 1A)
Catalyst
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Extreme risk factors.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- MOMENTUM:7.3>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:39d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.0=NEGATIVE
Warning (2)
- DEATH_CROSS:momentum=7.3>=5.0 recovering
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-0.03
Upside
-0.4%
Downside
15.0%
Sizing output
AVOID
SetupMomentum Cont — Trend continuation, RSI 67, MACD bullish
EdgeInst Constrain — Small cap ($1.5B) below institutional reach
SuitabilityAggressive — MCap $1.5B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 8.2 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:-0.0=NEGATIVE.
The strongest dimensions are Value at 8.2, Catalyst at 7.5, and Momentum at 7.3; the weakest are Technical at 2.2, Risk (lower is worse) at 2.6, and Peer rank at 4.4. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of -0.03 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Perfect Earnings Beat Streak
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P2Deep Value Analyst Conviction
Trip ifForward P/E multiple expands above 12x, reducing the discount to peers below a meaningful margin of safety.
- P3Confirmed Downtrend In Price
Trip ifThe 200-day moving average turns positive (slope exceeds 0% per month) and price holds above it for more than 4 consecutive weeks.
- P4Elevated Put Call Ratio Hedging Signal
Trip ifPut/call ratio falls below 3.0 for 2 consecutive weeks.